Neurogene

Compare

575 Followers

NGNE Stock Chart & Stats

$32.67

-$0.86(-3.93%)

At close: Jan 08 4:00 PM EST

$32.67

-$0.86(-3.93%)

Day’s Range― - ―

52-Week Range$6.88 - $74.49

Previous CloseN/A

Volume20.02K

Average Volume (3M)225.72K

Market Cap

$466.26M

Enterprise Value$51.22M

Total Cash (Recent Filing)$274.52M

Total Debt (Recent Filing)$10.97M

Price to Earnings (P/E)―

Beta2.72

Next Earnings

Nov 24, 2025

EPS Estimate

-1.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.05

Shares Outstanding14,271,916

10 Day Avg. Volume272,921

30 Day Avg. Volume225,725

Financial Highlights & Ratios

PEG Ratio-0.10

Price to Book (P/B)1.29

Price to Sales (P/S)434.14

P/FCF Ratio-5.62

Enterprise Value/Market Cap0.11

Enterprise Value/Revenue-55.38

Enterprise Value/Gross Profit-16.09

Enterprise Value/Ebitda-0.63

Forecast

1Y Price Target

$53.67

Price Target Upside64.28% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical ExpansionNeurogene has more than doubled its U.S. clinical footprint to 13 sites, positioning for rapid enrollment.

Regulatory ApprovalThe FDA formally cleared the registrational trial of NGN-401, offering earlier intervention and a broader label path.

Technological AdvantageICV delivery shows a consistent advantage across studies, achieving 10–100× greater transgene RNA expression in key brain regions compared to IT-L.

Bears Say

Financial StabilityThe net loss reported was $22M, which could be a concern for financial stability.

Regulatory ChallengesThe FDA indicated to management that it did not view 6-month data as clinically sufficient to support approval.

Neurogene News

Neurogene completes FDA discussion on Embolden trial, announces NGN-401 data

Neurogene (NGNE) announced the company has completed discussions with the FDA on its Embolden registrational trial protocol and...

22d ago

NGNE

Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright

H.C. Wainwright notes that Taysha Gene Therapies (TSHA) has added about $1.2B to its valuation after receiving Breakthrough...

29d ago

NGNE

TSHA

Neurogene Inc.’s NGN-401: A Promising Gene Therapy for Rett Syndrome

Neurogene Inc. (($NGNE)) announced an update on their ongoing clinical study. Neurogene Inc. is conducting a Phase 1/2...

4d ago

NGNE

Neurogene’s Strategic Advances and Expanded Embolden Trial Drive Buy Rating

William Blair analyst Sami Corwin has maintained their bullish stance on NGNE stock, giving a Buy rating today....

22d ago

NGNE

Neurogene’s Favorable Position in CNS Gene Therapy: Buy Rating Backed by Strategic Advantages and Competitive Valuation

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Neurogene today and set a price target of...

22d ago

NGNE

Neurogene Completes FDA Talks for Rett Syndrome Trial

An announcement from Neurogene ( ($NGNE) ) is now available. On October 9, 2025, Neurogene Inc. announced the...

22d ago

NGNE

Neurogene’s Strategic Advantage and Undervaluation: A Buy Recommendation with a $45 Target

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Neurogene and keeping the price target at...

29d ago

NGNE

Short Report: Viking Therapeutics short interest at 5-year high after VK273 data

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest...

2M ago

SMR

MLTX

Neurogene’s Clinical Progress and Financial Resilience Underpin Buy Rating Despite Regulatory Challenges

Analyst Mani Foroohar of Leerink Partners reiterated a Buy rating on Neurogene, with a price target of $70.00....

3M ago

NGNE

Positive Outlook for Neurogene: Buy Rating Affirmed Amid Clinical Progress and Strong Financial Position

TD Cowen analyst Ritu Baral has maintained their bullish stance on NGNE stock, giving a Buy rating yesterday....

3M ago

NGNE

Neurogene’s NGN-401 Gains Favorable Buy Rating Amid Promising Trial Design and Strong Safety Profile

Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Neurogene, retaining the price target of $45.00....

3M ago

NGNE

Neurogene Inc. Reports Increased Losses Amid R&D Focus

Neurogene Inc. ( ($NGNE) ) has released its Q2 earnings. Here is a breakdown of the information Neurogene...

3M ago

NGNE

Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome

An announcement from Neurogene ( ($NGNE) ) is now available. Neurogene Inc. announced significant progress in its NGN-401...

3M ago

NGNE

Neurogene says on track to share updated clinical efficacy and safety data

In addition to its update on registrational trial design for Embolden study, the company states: “Neurogene (NGNE) previously...

4M ago

NGNE

NGNE FAQ

What was Neurogene’s price range in the past 12 months?

Neurogene lowest stock price was $6.88 and its highest was $74.49 in the past 12 months.

What is Neurogene’s market cap?

Neurogene’s market cap is $466.26M.

When is Neurogene’s upcoming earnings report date?

Neurogene’s upcoming earnings report date is Nov 24, 2025 which is in 24 days.

How were Neurogene’s earnings last quarter?

Neurogene released its earnings results on Aug 11, 2025. The company reported -$1.05 earnings per share for the quarter, beating the consensus estimate of -$1.16 by $0.11.

Is Neurogene overvalued?

According to Wall Street analysts Neurogene’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Neurogene pay dividends?

Neurogene does not currently pay dividends.

What is Neurogene’s EPS estimate?

Neurogene’s EPS estimate is -1.25.

How many shares outstanding does Neurogene have?

Neurogene has 14,271,916 shares outstanding.

What happened to Neurogene’s price movement after its last earnings report?

Neurogene reported an EPS of -$1.05 in its last earnings report, beating expectations of -$1.16. Following the earnings report the stock price went down -5.553%.

Which hedge fund is a major shareholder of Neurogene?

Currently, no hedge funds are holding shares in NGNE

Neurogene Stock Smart Score

Underperform

Fundamentals

Return on Equity

-39.41%

Trailing 12-Months

Asset Growth

65.34%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Neurogene

Neurogene (NGNE) is a biotechnology company focused on developing life-changing genetic medicines to address severe neurological diseases. The company operates within the healthcare and biotechnology sectors, leveraging cutting-edge gene therapy techniques to create innovative treatments that have the potential to transform patient outcomes.

Neurogene (NGNE) Earnings & Revenues

Historic Earnings Reports

NGNE Stock 12 Month Forecast

Average Price Target

$53.67

▲(64.28% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","71":"$71","23.75":"$23.8","39.5":"$39.5","55.25":"$55.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$53.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,23.75,39.5,55.25,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.98,21.981538461538463,25.983076923076922,29.98461538461538,33.98615384615384,37.9876923076923,41.989230769230765,45.99076923076923,49.99230769230769,53.99384615384615,57.99538461538461,61.99692307692307,65.99846153846153,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.98,20.725384615384616,23.470769230769232,26.216153846153844,28.96153846153846,31.706923076923076,34.45230769230769,37.19769230769231,39.94307692307692,42.68846153846154,45.433846153846154,48.17923076923077,50.92461538461538,{"y":53.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.98,20.05846153846154,22.136923076923075,24.215384615384615,26.293846153846154,28.372307692307693,30.450769230769232,32.529230769230765,34.607692307692304,36.68615384615384,38.76461538461538,40.84307692307692,42.92153846153846,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.94,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.07,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.78,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.64,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >